2008;359:1343 56. 5. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of inten- sive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389 97. 6. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvas- tatin on progression of aortic stenosis: results of the Aortic Stenosis Pro- gression Observation: Measuring Effects Of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306 14. 7. Ochiai T, Saito S, Yamanaka F, et al. Renin-angiotensin system block- ade therapy after transcatheter aortic valve implantation. Heart. 2018;104:644 51. 8. Inohara T, Manandhar P, Kosinski AS, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320:2231 41. 9. O Brien KD, Zhao X-Q, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004;52:185 91. 10. Chockalingam A, Venkatesan S, Subramaniam T, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aor- tic Stenosis (SCOPE-AS). Am Heart J. 2004;147:E19. 11. Nadir MA, Wei L, Elder DHJ, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 2011;58:570 6. 12. Rieck E, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events. Hyper- tension. 2012;60:90 7. 13. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compli- ance impacts significantly on left ventricular afterload and function in aor- tic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005;46:291 8. CLINICAL STATEMENTS AND GUIDELINES 14. Moura LM, Ramos SF, Zamorano JL, et al. 